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Oncogenic ras Provokes Premature Cell
Senescence Associated with Accumulation
of p53 and p16INK4a
Manuel Serrano,*†‡ Athena W. Lin,* animal systems (reviewed by Hunter, 1991; Vogelstein
and Kinzler, 1993; see also Kemp et al., 1993).Mila E. McCurrach,* David Beach,*†
Together with ras mutations, inactivation of the tumorand Scott W. Lowe*
suppressors p53 and p16 are the most prevalent muta-*Cold Spring Harbor Laboratory
tions in human tumors (reviewed by Hirama and Koeffler,†Howard Hughes Medical Institute
1995; Hollstein et al., 1996). Micewith p53 gene deletionsCold Spring Harbor, New York 11724
develop normally but are highly prone to tumor develop-
ment (Donehower et al., 1992; Jacks et al., 1994). Indeed,
p53 is not required for normal cell growth, but acts toSummary
prevent proliferation under circumstances of cellular
stress. Hence, the normally low levels of p53 increaseOncogenic ras can transform most immortal rodent
following DNA damage, certain oncogenic insults, hyp-cells to a tumorigenic state. However, transformation
oxia, and a variety of other cellular stresses (reviewedof primary cells by ras requires either a cooperating
by Ko and Prives, 1996). Activation of p53 prevents celloncogene or the inactivation of tumor suppressors
proliferation by inducing either cell-cycle arrest orsuch as p53 or p16. Here we show that expression of
apoptosis. A variety of factors determine the probability
oncogenic ras in primary human or rodent cells results
of a particular outcome, including cell type, Rb activity,
in a permanent G1 arrest. The arrest induced by ras ectopic expression of certain oncogenes, and levels of
is accompanied by accumulation of p53 and p16, and proteins such as Bax, Bcl-2, and others (Ko and Prives,
is phenotypically indistinguishable from cellular senes- 1996; see also Lowe et al., 1993; McCurrach et al., 1997).
cence. Inactivation of either p53 or p16 prevents ras- p53 is a sequence-specific DNA-binding protein that
induced arrest in rodent cells, and E1A achieves a activates transcription of genes involved in cell-cycle
similar effect in human cells. These observations sug- arrest and in apoptosis. The expression of the cell-cycle
gest that the onset of cellular senescence does not inhibitor p21 is transcriptionally activated by p53 and
simply reflect the accumulation of cell divisions, but contributes to p53-dependent arrest (Ko and Prives,
can be prematurely activated in response to an onco- 1996).
genic stimulus. Negation of ras-induced senescence p16INK4a encodes a protein that associates with CDK4
may be relevant during multistep tumorigenesis. and inhibits its activity (Serrano et al., 1993; Xiong et
al., 1993), and is mutated in a wide variety of cancers
(reviewed by Hirama and Koeffler, 1995). Like p53, p16Introduction
has no obvious role in normal development or intrinsic
cell-cycle control but is a potent tumor suppressor.The ras family of proto-oncogenes encodes small GTP-
Hence, p16-deficient mice are viable but highly pronebinding proteins that transduce mitogenic signals from
to spontaneous and carcinogen-induced tumors (Ser-tyrosine-kinase receptors (reviewed by Barbacid, 1987;
rano et al., 1996). The primary function of the CDK4/Cahill et al., 1996). Amplification of ras proto-oncogenes
cyclin D kinases is to phosphorylate the retinoblastomaand mutations that constitutively activate Ras proteins
tumor suppressor protein, Rb, allowing progression ofare frequent in human cancers (reviewed by Bos, 1988).
the cell-cycle toward S phase (reviewed by Sherr andOncogenic ras efficiently transforms most immortal ro-
Roberts, 1995; Weinberg, 1995). Thus, expression of p16dent cell lines but fails to transform primary cells (New-
inhibits CDK4/D kinases and leads to G1 arrest, butbold and Overell, 1983). ras cooperates, however, with
is inconsequential in the absence of functional Rb. Incertain other oncogenic alterations to transform primary
contrast to p53, little is known about the regulation ofrodent cells (Land et al., 1983; Ruley, 1983), including
p16 expression or activity, or about circumstances in
overexpression of c-Myc, dominant negative p53,
which p16 might act physiologically to promote cell-
D-type cyclins, and Cdc25A and -B, and loss of p53,
cycle arrest.
p16, or IRF-1 (reviewed by Weinberg, 1989; Ruley, 1990; Primary murine fibroblasts lacking either p53 or p16
see also Hinds et al., 1994; Lovec et al., 1994; Tanaka are transformed by oncogenic ras alone (Tanaka et al.,
et al., 1994; Galaktionov et al., 1995; Serrano et al., 1996). 1994; Serrano et al., 1996) and are easily established
Several viral oncoproteins also cooperate with ras, in- into immortal cell lines (Harvey et al., 1993; Metz et al.,
cluding SV40 T-antigen, adenovirus E1A, human papillo- 1995; Serrano et al., 1996). In human cells, inactivation
mavirus E7, and HTLV-1 Tax (Weinberg, 1989; Ruley, of p53 and/or p16 also facilitates the immortalization
1990). When expressed alone, most of these cooperat- process (Reznikoff et al., 1996; Rogan et al., 1996). To-
ing alterations facilitate the establishment of primary gether, these observations suggest a role for p53 and
cells into immortal cell lines (Ruley, 1990). Oncogenic p16 in cellular senescence and, consistent with this,p53,
transformation of primary cells by coexpression of ras p21, and p16 levels and/or activity increase in senescent
and “immortalizing” mutations constitutes a model of cells (Alcorta et al., 1996; Hara et al., 1996; Reznikoff et
multistep tumorigenesis that has been reproduced in al., 1996). In this study, we demonstrate that prolonged
expression of oncogenic ras induces a cell-cycle arrest
involving p53 and p16 that is indistinguishable from cel-‡Present Address: Department of Immunology and Oncology,
lular senescence. We suggest that premature senes-Centro Nacional de Biotecnologı´a (CSIC), Campus de Cantoblanco,
Madrid, E-28049, Spain. cence is a mechanism of tumor suppression that can
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cells at day 1, but virtually none by day 3 (Figure 2C).
H-rasV12-transduced cells accumulated preferentially
in G1, with a cell-cycle profile indistinguishable from
serum-starved control cells (Figure 2C; data not shown).
The proportion of BrdU-positive cells in control popula-
tions was high, and declined only when cells reached
confluence between days 3 and 5 (Figure 2C). Similarly,
MEFs and REF52 cell populations transduced with
Figure 1. Experimental Design and Reference Time Frame H-rasV12 displayed reduced BrdU incorporation com-
pared tovector-transduced controls (see below). Hence,
explain several aspects of ras transformation and may the inability of the H-rasV12-transduced cells to prolifer-
be an important safeguard against neoplasia. ate is primarily due to cell-cycle arrest rather than cell
death. Cells arrested by oncogenic ras remained at-
Results tached to the plates and retained the same flat and
enlarged morphology for at least one month (data not
Oncogenic ras Provokes Cell Arrest shown). Thus, ras induces cell-cycle arrest prior to the
We chose three well-characterized systems to examine onset of S phase, and this program is conserved be-
the effects of oncogenic ras in normal cells: primary tween human and rodent fibroblasts.
(presenescent) human diploid fibroblasts (IMR90 and
WI38), primary mouse embryo fibroblasts (MEFs), and Cell-Cycle Proteins
the rat REF52 cell line. REF52 cells are immortal fibro- To characterize the nature of the cell-cycle arrest
blasts but are similar to primary cells in that they dis- caused by H-rasV12, we examined the expression of
play a high degree of growth control and require coex- several cell-cycle regulatory proteins by immunoblotting
pression of a cooperating oncogene for transformation (Figure 3A). Cell lysates were prepared between days 2
by ras (Franza et al., 1986). An activated ras allele and 4. In all three experimental systems, oncogenic ras
(H-rasV12) was introduced into these cells using recom- resulted in elevated p53 and p21. Furthermore, onco-
binant replication-deficient retroviruses as described in genic ras also increased p16 levels. On average, p53,
Experimental Procedures. The percentage of retrovirally p21, and p16 increases ranged between 10- and 20-
transduced cells ranged between 60% and 100%, as fold, compared to control cells and relative to the total
estimated in parallel infections using viruses expressing cellular protein content. Declines in the levels of hyper-
the lacZ gene product. The retroviral vectors coex- phosphorylated Rb, cyclin A, and CDK2 kinase activity
pressed a puromycin phosphotransferase gene that al- were also observed in H-rasV12-transduced cells (Fig-
lowed selection for pure populations of transduced cells ures 3A and 3B). Moderate increases in the levels of
within four days. The fifth day postinfection is desig- cyclin D1 were also observed in the presence of
nated day 0 in all the following experiments (Figure 1). H-rasV12 (data not shown), in agreement with previous
Using this protocol, we observed an approximate reports using immortal cell lines (Liu et al., 1995).
5- to 10-fold increase in total Ras protein, compared to Decreases in the abundance of hyperphosphorylated
endogenous Ras levels (data not shown). Rb, cyclin A, and CDK2 activity are characteristic fea-
Expression of H-rasV12 produced morphological tures of G0/G1 arrest; for example, during quiescence
changes in human IMR90 and WI38 cells. Initially, cells as a result of serum-starvation or confluence (see Dulic
displayed a refractile cytoplasm with thin and long pro- et al., 1993). Bycontrast, neither p53 nor p16 accumulate
jections (data not shown). By day 2, a significant propor- during quiescence (Afshari et al., 1993; Alcorta et al.,
tion of H-rasV12-transduced cells became flat and en- 1996). Consequently, the G1 arrest induced by onco-
larged; by day 6, virtually all cells had acquired the genic ras is different from quiescence and is specifically
enlarged morphology and apparently were growth ar- characterized by the simultaneous induction of the p53
rested (Figure 2A; data not shown for WI38). Similar and p16 tumor suppressor proteins.
changes in cell morphology were observed in primary
MEFs and REF52 cells (Figure 2A; data not shown for Cellular Senescence
WI38). No changes in morphology were detected in cell The features of H-rasV12-arrested cells described
populations transduced with empty viral vector (Fig- above are remarkably similar to cells that have sur-
ure 2A). passed their proliferative capacity and become senes-
The proliferative properties of such cell populations cent (Hayflick and Moorhead, 1961). For example, se-
were monitored by growth curves and by BrdU-labeling, nescent cells adopt a flat enlarged morphology and
followed by flow cytometry. Cells transduced with cease proliferation at subconfluent densities despite the
H-rasV12 or with empty vector were plated at low density presence of serum (reviewed by Stein and Dulic, 1995;
and cell numbers were counted (Figure 2B; data not Votja and Barrett, 1995). Also, senescent cells arrest
shown for WI38 cells). Control populations grew steadily with a G1 DNA content, and express increased levels
and reached confluence by day 6 (Figures 2A and 2B). and/or activity of p53, p21, and p16 (Noda et al., 1994;
By contrast, H-rasV12-transduced cells stopped accu- Atadja et al., 1995; Alcorta et al., 1996; Hara et al., 1996;
mulating well before reaching confluence (Figures 2A Reznikoff et al., 1996). To exlore further the potential
and 2B). BrdU incorporation combined with DNA-con- relationship between ras-induced arrest and senes-
tent analysis revealed that H-rasV12-transduced popu- cence, we examined three additional senescence-asso-
ciated markers: lack of serum-dependent induction oflations retained a small percentage of BrdU-positive
p53 and p16 in ras-Induced Senescence
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Figure 2. Effect of H-rasV12 on Primary Fibroblasts
The indicated cell-types were transduced with retroviruses expressing H-rasV12 or with empty-vector control (pBabe-Puro).
(A) Cell morphology at day 6. Photographs are at the same magnification.
(B) Representative growth curves corresponding to the indicated cell cultures transduced with empty vector (closed circles) or with H-rasV12-
expressing (open circles) retroviruses. The time frame corresponds to the scheme in Figure 1. Each curve was performed at least twice, and
each time point was determined in triplicate.
(C) Cell-cycle distribution of H-rasV12-expressing and control populations as measured by BrdU incorporation and DNA-content flow cytometry
analysis. Cells were stained with FITC-anti-BrdU to detect BrdU incorporation (vertical axis) and propidium iodide to detect total DNA (horizontal
axis). The upper box identifies cells incorporating BrdU (zS phase), the lower-left box identifies G0/G1 cells, and the lower-right box displays
G2/M cells. The percentage of cells incorporating BrdU is indicated in the upper left of each graph.
c-fos (Seshadri and Campisi, 1990), overexpression of produced no increase in the percentage of SA-b-gal-
the plasminogen activator inhibitor type-1 (PAI-1) gene positive cells in IMR90 control cells (Figure 4C and data
(Goldstein et al., 1994; Mu and Higgins, 1995), and de- not shown). Thus, the cell-cycle arrest induced by onco-
tection of a senescence-associated b-galactosidase genic ras was identical to replicative senescence by
(SA-b-gal) optimally active at a pH of 6.0 (Dimri et al., every criterion tested.
1995; see also Reznikoff et al., 1996).
To test induction of c-fos mRNA, IMR90 cells trans- E1A Bypass of Arrest
duced with H-rasV12 or with empty vector were serum
In rodent fibroblasts, the adenovirus E1A oncogene co-
starved from days 0 to 4, and then restimulated with
operates with H-rasV12 to transform primary cells onco-
serum. As expected, vector-transduced cells transiently
genically (Ruley, 1983). To determine whether E1A could
induced c-fos 30 min after restimulation (Figure 4A). No
circumvent ras-induced cell-cycle arrest, E1A was
c-fos message was detected, however, in H-rasV12-
transduced into MEF, REF52, and IMR90 cell popula-transduced cells (Figure 4A). PAI-1 regulates cell-extra-
tions using a vector coexpressing E1A 12S and hygro-cellular matrix interactions and is translated from two
mycin phosphotransferase. After selection in hygro-mRNAs. During senescence, both PAI-1 transcripts be-
mycin, E1A-expressing cells were infected with ancome elevated, but the increase in expression of the
H-rasV12-expressing or control virus, according to thesmall transcript is more pronounced (Mu and Higgins,
scheme in Figure 1. In each cell type, E1A-expressing1995). Likewise, H-rasV12-transduced IMR90 cells dis-
fibroblasts transduced with H-rasV12 incorporatedplayed a significant accumulation of PAI-1 mRNA, com-
BrdU with efficiencies comparable to those of cellspared with vector-transduced cells (2.5-fold large tran-
transduced with empty vector, and proliferated rapidlyscript; 7.5-fold small transcript) (Figure 4B).
(Figures 5 and 6). These results indicate that E1A effi-The SA-b-gal activity was assessed at several times
ciently negates the cell-cycle arrest induced by onco-postinfection (Figure 4C). The percentage of SA-b-gal-
genic ras, and are consistent with the observation thatpositive cells in H-rasV12-expressing populations was
E1A cooperates with ras in transformation assays. Im-initially low, but increased at day 3 and reached 60%
portantly, the levels of H-Ras proteins following intro-by day 6 (Figures 4C and 4D). In contrast, about 3%
duction of H-rasV12 were similar between parental andof the IMR90 cells in control cultures were SA-b-gal
E1A-expressing cells (data not shown), demonstratingpositive, a value consistent with that previously de-
that overexpression of H-rasV12 is not necessarily detri-scribed for young IMR90 cells (Dimri et al., 1995). Cell-
cycle arrest produced by serum depletion or confluence mental to cell proliferation.
Cell
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Figure 3. Effect of H-rasV12 on Cell-Cycle Regulatory Proteins
(A) Immunoblots of cellular lysates corresponding to cells trans-
duced with empty vector (V) or with H-rasV12-expressing (R) retrovi-
ruses. Our anti-p16 antibodies did not crossreact with rat p16, so
we could not examine p16 expression in REF52 cells.
(B) CDK2 kinase activity against histone H1 obtained after immuno-
precipitation of the indicated cellular lysates, (V) or (R) as in (A), with
anti-CDK2 in the absence (2) or presence (1) of competing antigenic
peptide.
Both MEF and IMR90 cells expressing E1A alone dis-
played a normal rate of BrdU incorporation, but cell
numbers accumulated slowly (compare Figures 5A and
5C with Figures 6A and 6C, respectively). This discrep-
ancy presumably reflects a high rate of apoptosis oc-
Figure 4. Senescent Features of the H-rasV12-Transduced Cellscurring in the E1A-expressing cells (Lowe et al., 1994).
Notably, primary MEFs and REF52 cells expressing E1A (A) Expression of c-fos in response to serum restimulation in IMR90
cells transduced with empty vector or with H-rasV12-expressingwere morphologically altered and appeared oncogeni-
retroviruses. At day 0 (see Figure 1), cultures were serum-deprivedcally transformed following introduction of H-rasV12
(s.d.) in 0.5% serum for 96 hr and then restimulated by addition of(data not shown). E1A also altered the morphology of
10% serum. At the indicated times after restimulation, total RNA
IMR90 cells. In contrast to rodent cells, however, IMR90 was prepared and probed with c-fos and GAPDH as a loading con-
cells expressing E1A and transduced with H-rasV12 re- trol. The c-fos probe crossreacted with 28S ribosomal RNA.
mained growing as monolayers and displayed no indica- (B) Expression of plasminogen activator inhibitor type-1 (PAI-1) in
IMR90 cells transduced with empty vector (V) or with H-rasV12-tion of neoplastic transformation (see Figure 7B).
expressing (R) retroviruses at day 6. The two transcripts of PAI-1
are indicated (see Mu and Higgins, 1995).
(C) b-gal (pH 6.0) activity in proliferating (prol.) or serum-deprivedDisruption of p53 or p16/Rb Pathways
(s.d.) IMR90 cells, and in cells transduced with H-rasV12-expressing
To examine the independent contribution of p53 and retrovirus at the indicated days.
p16 to ras-induced cell-cycle arrest, the response of (D) Photographs of the indicated IMR90 cells stained for b-gal (pH
wild-type MEFs to oncogenic ras was compared to oth- 6.0) activity at day 6. Photographs are at the same magnification.
erwise identical MEFs derived from p53- or p16-defi-
cient mice (Jacks et al., 1994; Serrano et al., 1996). In
contrast to wild-type MEFs, p532/2 or p162/2 MEFs con- H-rasV12 was transduced (data not shown). These re-
sults indicate that p53 and p16 are essential for ras-tinued to incorporate BrdU and proliferate following in-
troduction of H-rasV12 (Figures 5A and 6A). In agree- induced arrest in MEFs, and that inactivation of either
p53 or p16 alone is sufficient to circumvent arrest.ment with previous reports (Tanaka et al., 1994; Serrano
et al., 1996), both p532/2 and p162/2 MEFs expressing In REF52 and IMR90 fibroblasts, a different approach
was needed to disrupt p53 or the p16/Rb pathway. ToH-rasV12 displayed features of oncogenic transforma-
tion (e.g., refractile morphology, loss of contact inhibi- inactivate p53 specifically, we transduced p53175H, a
dominant-negative p53 mutant, in the same manner astion), which were apparent almost immediately after
p53 and p16 in ras-Induced Senescence
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Figure 5. Genetic Analysis of H-rasV12-
Induced Arrest: BrdU Incorporation at Day 2
The indicated cell typeswere transduced with
empty vector (solid bars) or with H-rasV12-
expressing (shaded bars) retroviruses. BrdU
incorporation was detected by immunofluo-
rescence. The average of two experiments is
shown, and at least 200 cells were counted
per experiment.
(A) Mouse embryo fibroblasts (MEF) of wild-
type genotype containing empty vector or ex-
pressing E1A, MEF-p532/2, or MEF-p162/2, as
indicated.
(B) REF52 cells containing empty vector or
expressing the indicated proteins.
(C) IMR90 cells containing empty vector or
expressing the indicated proteins.
was described for E1A (see Experimental Procedures). sufficient to prevent ras-induced arrest in rodent but not
in human fibroblasts.Transduction of dominant-negative p53 inactivated en-
dogenous p53, as judged by its ability to abolish p21
expression (data not shown). To disrupt the p16/Rb Absence of Senescence-Associated Markers
pathway, we sequentially transduced cyclin D1 and in Cells Coexpressing E1A
CDK4R24C using different selectable markers (see Experi- and Oncogenic ras
mental Procedures). CDK4R24C is a mutant CDK4 protein To test further the significance of the senescence mark-
insensitive to p16 (Wo¨lfel et al., 1995), and cooperates ers induced by H-rasV12 in IMR90 cells (see above),
with cyclin D1 to prevent cell-cycle arrest induced by we examined the behavior of these markers in IMR90
p16 overexpression (Bartkova et al., 1996; J. Koh and cells expressing E1A and transduced with H-rasV12.
E. Harlow, personal communication). The cyclin D1/ H-rasV12 failed to induce PAI-1 expression or SA-b-gal
CDK4R24C complexes are expected to inactivate the p16/ activity in IMR90 cells expressing E1A (Figures 7A and
Rb pathway by phosphorylating Rb in a p16-insensitive 7B). The response of c-fos to serum stimulation could
manner, and possibly by sequestering other cell-cycle not be assessed because E1A-expressing cells under-
inhibitors such as p21 and p27. go apoptosis following serum depletion (Lowe and
Disruption of p53 activity compromised ras-induced Ruley, 1993; Lowe et al., 1994). These results indicate
arrest in REF52 cells but not in IMR90 cells. Specifically, that overexpression of PAI-1 and the presence of SA-b-
REF52/p53175H populations transduced with H-rasV12 gal activity are not direct consequences of oncogenic
showed a partial decrease in BrdU incorporation at day ras, but rather are associated with the arrested state
2, but eventually outgrew the vector-transduced REF52/ induced by ras. In this regard, our observations further
p53175H (Figures 5B and 6B). Concordant with previously strengthen the association of these markers with cellular
published results (Hicks et al., 1991), REF52 cells coex- senescence.
pressing mutant p53 and ras appeared morphologically
transformed (data not shown). In contrast, IMR90/p53175H
Discussioncells transduced with H-rasV12 underwent cell-cycle ar-
restand displayed the large flat morphologycharacteris-
The effect of ras on proliferation and tumorigenesis hastic of the parental cells expressing H-rasV12 alone (Fig-
been well documented in the context of immortal cellures 5C and 6C, and data not shown). Thus, whereas p53
lines (Barbacid, 1987; Cahill et al., 1996). However, theis essential for ras-induced arrest in rodent fibroblasts, it
analysis of the effects of prolonged ras expression inappears dispensable in human fibroblasts.
primary cells has remained largely unexplored, mainlySimilarly, disruption of the p16/Rb pathway by cyclin
due to the limited lifespan of primary cells and to theD1/CDK4R24C allowed escape from ras-induced arrest in
low efficiencies of conventional gene transfer methods.REF52 but not in IMR90 fibroblasts. Hence, in agreement
Retrovirus-mediated gene-transfer allows the introduc-with the behavior of p162/2 MEFs, REF52 cells coex-
tion of exogenous genes with high efficiencies, suchpressing cyclin D1 and p16-insensitive CDK4R24C contin-
that the effects of a transduced gene can be assessedued incorporating BrdU and proliferating upon introduc-
in whole cell populations without significant expansiontion of H-rasV12 (Figures 5B and 6B). Moreover, these
of the culture. We took advantage of these methods tocells became small and refractile, and showed loss of
study the effects of oncogenic ras in primary cells.contact inhibiton, which are both characteristics of neo-
plastic transformation (data not shown). In contrast,
Cell-Cycle Arrest Induced by Oncogenic rastransfer of H-rasV12 into IMR90 populations coexpress-
We showthat ras provokes a permanent cell-cycle arresting cyclin D1 and CDK4R24C elicited the same changes
in primary fibroblasts of rodent and human origin. Thein cell morphology and growth as in control IMR90 cells.
arrest occurs at G1 and in association with a significantThus, cells became large and flat, and displayed a signif-
increase in the abundance of p53, p21, and p16. In thisicant decrease in BrdU incorporation and growth rate
regard, oncogenic activation of ras constitutes a novel(Figures 5C and 6C). In a parallel situation to that de-
scribed for p53, disruption of the p16/Rb pathway is circumstance in which p53 is activated, and provides a
Cell
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Figure 7. Absence of Senescence Markers in IMR90 Cells Express-
ing E1A and H-rasV12
(A) Expression of plasminogen activator inhibitor type-1 (PAI-1) at
day 6 in IMR90 cells containing empty vector orexpressing H-rasV12
alone, or in combination with E1A, as indicated. The two transcripts
of PAI-1 are indicated.
(B) Photographs of the indicated IMR90 cells stained for b-gal (pH
6.0) activity at day 6. Photographs are at the same magnification.
oncoprotein allows escape from ras-induced arrest. The
differential sensitivity between human and rodent cells
to individual perturbation of p53 or the p16/Rb pathway
may underlie the well-known difficulty in establishing
and transforming human cell lines in culture.
Several observations indicate that ras-induced arrest
is not an immediate outcome of Ras signaling, but rather
a cellular response to aberrant Ras activity. The immedi-
ate effect of Ras in primary cells is mitogenic, as indi-
cated by microinjection studies in primary human andFigure 6. Genetic Analysis of H-rasV12-Induced Arrest: Growth
Curves rodent fibroblasts (Lumpkin et al., 1986; Sullivan et al.,
1986; Serrano et al., 1995). Also, the cell-cycle arrestThe indicated cell types were transduced with empty vector (closed
circles) or with H-rasV12-expressing (open circles) retroviruses. A induced by ras inour studies is not immediate butoccurs
representative experiment is shown. Each experiment was per- after a lag period, typically becoming complete by day
formed at least twice, and each time point was determined in trip- 2 of the experimental scheme shown in Figure 1 (day 7
licate.
after the intitial introduction of H-rasV12). This delayed(A) Mouse embryo fibroblasts (MEF) of wild-type genotype con-
response is consistent with the existence of a homeo-taining empty vector or expressing E1A, MEF-p532/2, or MEF-p162/2,
static mechanism that prevents proliferation after pro-as indicated.
(B) REF52 cells containing empty vector or expressing the indicated longed Ras activation and that is mediated, at least in
proteins. part, by the induction of p53 and p16.
(C) IMR90 cells containing empty vector or expressing the indicated Antiproliferative responses to oncogenic ras are not
proteins.
unprecedented. Oncogenic ras has been reported to
result in proliferation arrest in REF52 fibroblasts (Franza
et al., 1986; Hirakawa and Ruley, 1988) and in primarydescription of a stimulus that can induce p16 in associa-
tion with cell-cycle arrest. It has been previously re- rat Schwann cells (Ridley et al., 1988). Oncogenic ras
also induces proliferative arrest and differentiation inported that cells lacking functional Rb overexpress p16
(Serrano et al., 1993; Hara et al., 1996). However, the two rodent cell lines, rat pheochromocytoma PC12 cells
and mouse NIH-3T3-L1 fibroblasts (Bar-Sagi and Fera-absence of functional Rb renders the cells insensitive
to p16 and cells proliferate in the face of high levels of misco, 1985; Benito et al., 1991; Marshall, 1995). How-
ever, it is important to point out that microinjection ofp16 protein.
In rodent fibroblasts, disruption of either p53 or p16 Ras into Schwann and PC12 cells immediately results
inproliferative arrest ordifferentiation, respectively (Bar-alone is sufficient to prevent ras-induced arrest. p53
and p16 are not thought to promote cell-cycle arrest Sagi and Feramisco, 1985; Ridley et al., 1988). This is
in contrast to primary fibroblasts, where microinjectionthrough the same pathway; consistent with this, p16
levels increase in response to ras in p532/2 MEFs, and of Ras initially results in proliferation (Lumpkin et al.,
1986; Sullivan et al., 1986) and probably reflects cell–p53 levels increase in p162/2 MEFs (data not shown).
Thus, ras-induced accumulation is achieved by the two type specific differences.
proteins independently of one another and, at the levels
achieved, neither alone is sufficient to promote arrest. Senescence Induced by Oncogenic ras
The cell-cycle arrest induced by oncogenic ras is pheno-E1A is a viral oncoprotein known to inactivate Rb and
to override p53-mediated arrest (Lowe et al., 1993). In typically similar, and perhaps identical, to cellular sen-
escence. Senescence was originally defined by thenormal human fibroblasts, by contrast, independent dis-
ruption of either p53 or the p16/Rb pathway alone is not observation that primary fibroblasts have a limited prolif-
erative capacity that is genetically determined (Hayflicksufficient to prevent ras-induced arrest, but the E1A
p53 and p16 in ras-Induced Senescence
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and Moorhead, 1961; Ro¨hme, 1981; Votja and Barrett, Cell-cycle arrest in response to oncogenic ras may
provide selective pressure to mutate p53 and p16 during1995). At the end of their lifespan, cells undergo changes
carcinogenesis. Consistent with this view, mutationand/in morphology, physiology, and gene expression, and
or amplification of K-ras and loss of p16 and p53 arepermanently cease proliferation (Stein and Dulic, 1995).
extremely common in human pancreatic cancers (Bos,In this state, cells remain metabolically active for long
1988; Caldas et al., 1994). In colorectal cancer, mutationperiods of time.
and/or amplification of K-ras typically precedes p53 mu-Under normal culture conditions, induction of senes-
tation (reviewed by Kinzler and Vogelstein, 1996). In ani-cence depends solely on the accumulated number of
mal models, p53 deficiency accelerates tumor progres-cell doublings. However, a phenotype suggestive of pre-
sion in ras-transgenic mice (Kemp et al., 1993), andmature senescence can be induced following exposure
mice lacking p16 rapidly develop malignant tumors byof cell cultures to DNA-demethylating drugs (Holliday,
treatment with DMBA (Serrano et al., 1996), a carcinogen1986; Fairweather et al., 1987), ceramide (Venable et al.,
that efficiently mutates H-ras (reviewed by Barbacid,1995), or inhibitors of histone deacetylation (Ogryzko et
1987).al., 1996). In addition, the existence of multiple potential
It is possible that the effects of oncogenic ras expres-pathways that can promote senescence is supported
sion that we observed may not precisely reflect cellularby cell fusion studies (Votja and Barrett, 1995). Based
responses to ras mutation in vivo. Of note, we introducedon our observations, we envision that senescence oc-
ras into whole cell populations and, consequently, Rascurs not merely as a passive consequence of a cell-
levels among individual cells may vary. Yet, despite thisdivision counting mechanism, but rather as a dynamic
intrinsic variability, the individual cell responses are re-response to an aggressive mitogenic stimulus. In this
markably uniform: the vast majority of cells arrest uponregard, it is possible that the normal Hayflick limit re-
transduction of ras, and the arrest program is conservedflects the accumulated mitogenic load that occurs dur-
between fibroblasts from three species. A similar vari-ing the lifetime of a cell culture.
ability in ras expression is also presumed in tumors,
particularly in those tumors where ras proto-oncogenesOncogene Cooperation and
are amplified (Bos, 1988). We speculate that the intensityMultistep Carcinogenesis
of the ras oncogenic stimulus may affect the lag periodDisruption of p53 or the p16/Rb pathway in rodent cells
that precedes the induction of the cellular antiprolifera-is extremely efficient at abrogating ras-induced arrest.
tive response described here.In fact, oncogenic ras alone transforms primary mouse
fibroblasts deficient in either p53 or p16 (Tanaka et al.,
Concluding Remark1994; Serrano et al., 1996). Hence, escape from ras-
We demonstrate that oncogenic ras provokes prema-induced arrest may be sufficient for transformation by
ture senescence in primary rodent and human cells inoncogenic ras. Other alterations known to cooperate
association with the induction of p53 and p16. We pro-with ras also disrupt p53 or the p16/Rb pathway. For
pose that premature induction of senescence in re-example, T-antigen inactivates p53 and Rb; cyclin D1
sponse to abnormal mitogenic signaling is a mechanisminactivates Rb by promoting its phosphorylation; the
of tumor suppression. Inactivation of this antiprolifera-viral oncoprotein Tax inactivates p16 (Suzuki et al.,
tive response allows proliferation to continue unabated1996); the Cdc25A and -B phosphatases can activate
in the presence of oncogenic stimuli. These observa-CDK2, leading to Rb inactivation; and, finally, Myc acti-
tions could explain the apparent pressure to mutatevates the expression of Cdc25A and -B (Galaktionov
genes involved in the establishment of oncogene-et al., 1996). We propose that the cell-cycle activation
induced senescence, such as p53 and p16, during tumor
associated with disruption of p53 or the p16/Rb pathway
progression.
is necessary for transformation by oncogenic ras.
The induction of a premature senescence program by Experimental Procedures
oncogenic ras provides an explanation for the coopera-
tion between ras and the immortalizing mutations that Retroviral Vectors
The following plasmids were used for generating retroviruses:transform primary rodent cells (see Introduction). Muta-
pBabe (Morgenstern and Land, 1990); pLPC (coexpresses the genetions that facilitate immortalization may disable not only
of interest from an internal CMV promoter with a puromycin resis-the senescence program associated with the accumula-
tance gene driven by the LTR); and pWZL (coexpresses the gene
tion of cell doublings but also, and perhaps more impor- of interest with a selectable marker translated from an internal ribo-
tantly, they may impair ras-induced senescence. Simi- somal entry site) (a gift of J. Morgenstern). Oncogenic ras was trans-
duced using a pBabe-Puro-based vector expressing a humanlarly, most spontaneously immortalized rodent cells can
H-rasV12 cDNA (pBabe-ras), although transduction of H-rasV12 usingbe transformed by ras alone, suggesting that ras-
pLPC, pWZL-Hygro, or pWZL-CD8 (pWZL8ras coexpressing a CD8induced senescence is impaired. Indeed, mutations in
cell-surface marker) gave similar results (data not shown). pWZL-
p53 and p16 often occur spontaneously during the es- Hygro derivatives were used to generate retroviruses expressing
tablishment of immortal cell lines (Harvey and Levine, the following proteins: an adenovirus-5 12S cDNA (pWZL12S); a
1991; Reznikoff et al., 1996; Rogan et al., 1996). The human p53175H mutant (pWZLp53.175); and the p16-insensitive
CDK4R24C mutant (pWZLR24C). A pWZL-Neo derivative was used toH-rasV12 allele used in this study was originally isolated
express the ecotropic retroviral receptor (pWZL-Neo-EcoR), and afrom tumor-derived DNA by its ability to transform NIH-
pLPC derivative was used to express cyclin D1 (pLPCD1).3T3 cells, an immortal rodent cell line (Barbacid, 1987).
Interestingly, it is now known that NIH-3T3 cells have Cell Culture and Preparation of MEFs
deleted the p16 gene (Quelle et al., 1995; Linardopoulos Human primary fibroblasts (IMR90, WI38) and an amphotrophic ret-
rovirus packaging line (BING) were obtained from ATCC. REF52et al., 1995).
Cell
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cells were obtained from Cold Spring Harbor Laboratory. The eco- Immunoblot Analysis
Cells were washed with ice-cold PBS and lysed in NP-40 lysis buffertropic virus packaging line Phoenix was obtained from G. Nolan.
MEFs were prepared from day 13.5 embryos derived from crosses (150 mM NaCl, 1.0% NP-40, 50 mM Tris–HCl [pH 8.0], 1 mM phenyl-
methylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mM sodium vanadate,between either p531/2 mice (Jacks et al., 1994) or p161/2 mice (Ser-
rano et al., 1996). The head and the red organs were removed, then 1 mM EDTA). After 30 min on ice, lysates were cleared by centrifuga-
tion. Samples corresponding to 15 mg of protein (BIO–RAD proteinthe torso was minced and dispersed in 0.1% trypsin (45 min at
378C). Cells were grown for two population doublings and then assay) were separated on 10% or 15% SDS–PAGE gels and trans-
ferred to Immobilon-P membranes (Millipore). Western blot analysisfrozen. The wild-type MEFs used for comparison were derived from
the same crosses, and their behavior was identical regardless of was accomplished according to standard procedures using ECL
detection (Amersham). The following primary antibodies were usedtheir provenance (p531/2 cross or p161/2 cross). Human fibroblasts
were used between 20 and 30 population doubling levels (PDLs); (1:1000 unless otherwise indicated): CM5 and CM1 (Novacastra) for
human and rodent p53, respectively; 1 mg/ml WAF1 Ab1 (OncogeneMEFs between 3 and 5 PDLs. All cultures were maintained in DMEM
(GIBCO) plus 10% fetal bovine serum (FBS; Sigma). Primary human Sciences) for human p21; an affinity-purified rabbit polyclonal anti-
body (Brugarolas et al., 1995) for rodent p21; DCS-50 (Novocastra)and mouse fibroblasts were subcultured 1:4 upon reaching conflu-
ence; each passage was considered two PDLs. for human p16; M-156 (Santa Cruz) for mouse p16; a mixture of 0.5
mg/ml G3–245 mouse antibody (Pharmingen) and 1:100 dilutions of
the C-36 and XZ-55 hybridoma culture supernatants; and a rabbitRetroviral-Mediated Gene Transfer
polyclonal antiserum against GST-human cyclin A for human andPhoenix cells (5 3 106) were plated in a 10 cm dish, incubated for
rodent cyclin A. Horseradish peroxidase-conjugated donkey anti-24 hr, and then transfected by calcium-phosphate precipitation with
rabbit or sheep anti-mouse antibodies (Amersham) were used as20 mg of a retroviral plasmid (15 hr at 378C). After 48 hr, the virus-
secondary antibodies.containing medium was filtered (0.45 mm filter, Millipore) andsupple-
mented with 4 mg/ml polybrene (Sigma) (first supernatant). Viruses
were collected for an additional 8 hr as before (second supernatant). CDK2 Kinase Assays
Target fibroblasts were plated at 8 3 105 cells per 10 cm dish and Anti-CDK2 immunoprecipitates (Xiong et al., 1993) were washed
incubated overnight. For infections, the culture medium was re- two additional times with kinase buffer (20 mM Tris–HCl [pH 8.0],
placed by the appropriate first supernatant, and then the culture 10 mM MgCl2, 1 mM EDTA, 1 mM DTT), and bead suspensions (z10
plates were centrifuged (1 hr, 1500 rpm) and incubated at 378C for ml) were brought to 20 ml with a solution containing 2.5 mg of histone
8 hr. The infection process was repeated using the second superna- H1 (Boehringer) and 10 mCi of [g-32P]ATP (3000 Ci/mmol). Reaction
tant. One plate of Phoenix cells produced sufficient virus for one to mixtures were incubated for 15 min at room temperature and re-
two plates of target cells. Sixteen hours later, infected cell popula- solved on 10% SDS–PAGE gels. H1 kinase activity was quantified
tions were purified using the appropriate selection: 2 mg/ml puromy- using a Fuji Phosphorimager.
cin; 75 mg/ml hygromycin; or 200 mg/ml or 400 mg/ml G418 (IMR90
and REF52 cells, respectively). Cells infected with WZL-CD8-based Northern Blots
vectors were gently trypsinized and purified using magnetic beads Total RNA was isolated from subconfluent cultures (Trizol, GIBCO–
conjugated to anti-CD8 (Dynal). Multiple genes were introduced BRL). Ten micrograms was resolved by electrophoresis, transferred
sequentially, with the appropriate drug selection between. The eco- to Hybond-N1 membranes, and probed according to standard pro-
tropic retrovirus receptor was introduced into human and rat fibro- cedures. The 1 kb Pst1 fragment from v-fos (kindly provided by R.
blasts (IMR90, WI38, and REF52) by first infecting cell populations Maestro and S. Rizzo) was used to assess c-fos expression. The
with an amphotropic vector (pWZL-Neo-EcoR [a gift of D. Conklin] DNA probe for human PAI-1 was purchased from Genome Systems
produced in BING cells), allowing subsequent infection with eco- (clone 268918; locus N35838).
tropic viruses.
Senescence-Associated b-Galactosidase
Growth Curves SA-b-gal activity was detected as previously described (Dimri et al.,
Twenty-five thousand cells per well were plated into 12-well plates. 1995) with slight modifications. Cells were washed once with PBS
At the indicated times, cells were washed with PBS, fixed in 10% (pH 7.2), fixed with 0.5% glutaraldehyde (PBS [pH 7.2]), and washed
formalin, and rinsed with distilled water. Cells were stained with in PBS (pH 7.2) supplemented with 1 mM MgCl2. Cells were stained
0.1% crystal violet (Sigma) for 30 min, rinsed extensively, and dried. in X-gal solution (1 mg/ml X-gal [Boehringer], 0.12 mM K3Fe[CN]6,
Cell-associated dye was extracted with 2.0 ml 10% acetic acid. 0.12 mM K4Fe[CN]6, 1 mM MgCl2 in PBS at pH 6.0) overnight at 378C.
Aliquots were diluted 1:4 with H2O, transferred to 96-well microtiter
plates, and the optical density at 590 nm was determined. Values Acknowledgments
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